Pharmalink raises SEK100M to advance Nefecon® development as new treatment for kidney disease

Pharmalink announces positive result in Phase 2b Trial of Nefecon®

Pharmalink acquires novel therapeutic product candidate for treating inflammation associated with osteoarthritis

Pharmalink announces an open Investigational New Drug (IND) application for Nefecon®